Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Eagle Pharmaceuticals excels in 2022 with strong earnings growth

Eagle Pharmaceuticals' 2022 performance reflects strong earnings growth and operational efficiency, supported by key product sales and financial stability.
While facing challenges in managing expenses amidst investments, the company's strategic strengths lie in its product portfolio and financial resilience.
Opportunities for revenue growth and market expansion present avenues for Eagle Pharmaceuticals to further enhance its competitive position and drive future success.

Eagle Pharmaceuticals posts robust Q1 results, eyes strategic growth opportunities

Eagle Pharmaceuticals delivered a strong financial performance in Q1 2023, driven by key product sales and market share retention.
While facing challenges in expenses management, the company's solid cash position and growth strategies position it well for future opportunities.
Strategic initiatives like potential acquisitions and market expansion underscore Eagle Pharmaceuticals' commitment to sustained growth and innovation.

Eagle Pharmaceuticals beats Q2 estimates, eyes growth through strategic investments

Eagle Pharmaceuticals delivered a robust Q2 performance, exceeding expectations and demonstrating strong financial health. The company's strategic investments in R&D and commercial infrastructure position it well for future growth. Despite challenges and uncertainties, Eagle Pharmaceuticals remains optimistic about its continued growth trajectory and market prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens.

Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company will host an Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET.

SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

-- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early as the beginning of 2023 -- -- Interim results expected approximately one year after patient enrollment begins --

Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumoni

-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA with eligibility for a priority review voucher -- -- The compound is also being developed for post-operative respiratory depression and community drug overdose --

Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant

-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depression -- -- Development is under way of intramuscular formulation for treatment of community drug overdose and as a medical countermeasure for mass casualty events --

Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference as follows:

Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that Eagle's vasopressin product does not infringe on any of the patents asserted by Par Pharmaceutical, Inc. (“Par”).

Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – President and Chief Executive Officer Mike Greenberg – Vice President-Medical Affairs Brian Cahill – Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair David Amsellem – Piper Sandler Operator Good morning, everyone. My name is Katie and I will be your conference operator.

Eagle Pharmaceuticals, Inc's (EGRX) CEO Scott Tarriff on Q2 2022 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share

Eagle Pharmaceuticals Reports Second Quarter 2022 Results

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter --

Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial.

Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has completed the acquisition of the entire issued share capital of Acacia Pharma Group plc (“Acacia Pharma”) (EURONEXT: ACPH) by way of a scheme of arrangement under Part 26 of the United Kingdom's Companies Act 2006 (the “Transaction”).

Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

APA Corporation

Cabot

Griffon

Meritage Homes

One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.

Press the Buy Button on These 5 High Earnings Yield Picks Now

-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- -- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health's Type C meeting --

Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as follows:

Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - Founder, President, CEO & Director Brian Cahill - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Lachlan Hanbury-Brown - William Blair & Company David Amsellem - Piper Sandler & Co. Operator Good morning, everyone. My name is Gretchen, and I'll be your conference operator.

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2022 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates

WOODCLIFF LAKE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three months ended March 31, 2022.

Eagle Pharmaceuticals Reports First Quarter 2022 Results

WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens.

Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022

WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Hospira, Inc (“Hospira”). Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application (“NDA”) referencing BENDEKA ® . The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances.

Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

Here is how Eagle Pharmaceuticals (EGRX) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?

Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has agreed to acquire Acacia Pharma Group plc for approximately €94.7 million, equivalent to €0.90 per share. Each shareholder of Acacia Pharma would receive, as consideration for each share of Acacia Pharma held by such shareholder.

Eagle Pharma Adds Hospital-Based Products With €95M Acacia Pharma Deal

WOODCLIFF LAKE, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc (“Acacia Pharma”) (EURONEXT: ACPH) to Eagle by way of a scheme of arrangement under Part 26 of the United Kingdom's Companies Act 2006 (the “Scheme”).

Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2021 Results - Earnings Call Transcript

News for Eagle Pharmaceuticals Stock (EGRX)